Sort   by:  
 Page size 
GenomicsEpigenome analysis of parental and ABT-199 resistant AML cell lines
Epigenome analysis of parental and ABT-199 resistant AML cell lines
PRJNA795503 | ENA
Methylation profilingEpigenome analysis of parental and ABT-199 resistant AML cell lines
Genome wide DNA methylation profiling of parental, ABT-199 resistant population, and ABT-199 resistant clones from 3 acute myelogenous leukemia (AML) cell lines (MOLM-13, MV-4-11, OCI-AMLO2). The Illumina Infinium MethylationEPIC Human DNA methylation Beadchip was used to obtain DNA methylation prof...
ORGANISM(S): Homo sapiens 
2022-01-12 | GSE193254 | GEO
ProteomicsBCL2 amplicon loss and super-enhancer remodeling drives ABT-199 resistance
Drug-tolerant “persister” tumor cells underlie the emergence of drug-resistant clones contribute to relapse and disease progression; thus, identifying actionable targets that disable persisters and mitigate relapse are a high priority need. Although the BCL2-targeting agent venetoclax (ABT-199) has ...
ORGANISM(S): Homo sapiens (Human) 
2020-05-26 | PXD010193 | Pride
Abpp Lymphoma Persister Apoptosis 
GenomicsThe spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL
The spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL
PRJNA708347 | ENA
GenomicsChromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [ChIP-seq]
Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [ChIP-seq]
PRJNA477330 | ENA
GenomicsComparing gene expression in ABT-199 (venetoclax) sensitive and resistant diffuse large B cell lymphoma cell (DLBCL) lines
Comparing gene expression in ABT-199 (venetoclax) sensitive and resistant diffuse large B cell lymphoma cell (DLBCL) lines
PRJNA1059617 | ENA
TranscriptomicsThe spleen as a sanctuary site for residual leukemic cells following ABT-199 monotherapy in ETP-ALL
Two mice in which luciferase-positive LOUCY ETP-ALL cells were xenografted were treated with either vehicle or ABT-199 (50 mg/kg) for 11 days. Afterwards, single cells suspensions were made from bone marrow and spleen of both mice for 10x Genomics scRNA-seq. Following quality control, a total of 13,...
ORGANISM(S): Homo sapiens Mus musculus 
2021-03-10 | GSE168594 | GEO
GenomicsChromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [RNA-seq]
Chromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [RNA-seq]
PRJNA477352 | ENA
GenomicsChromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [ChIP-seq]
Drug-tolerant “persister” cells underlie the emergence of drug-resistant clones and allow residual tumors to survive therapy; thus, represent an attractive therapeutic target to mitigate relapse. With the promising outcome, yet some resistance cases surfaced after the approval of venetoclax (ABT-199...
ORGANISM(S): Homo sapiens 
2019-05-01 | GSE116097 | GEO
TranscriptomicsChromosomal deletion and chromatin remodeling Drive ABT-199 Resistance in B-cell Lymphomas [RNA-seq]
Drug-tolerant “persister” cells underlie the emergence of drug-resistant clones and allow residual tumors to survive therapy; thus, represent an attractive therapeutic target to mitigate relapse. With the promising outcome, yet some resistance cases surfaced after the approval of venetoclax (ABT-199...
ORGANISM(S): Homo sapiens 
2019-05-01 | GSE116129 | GEO
Sort   by:  
 Page size